Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bffd16ff27899205c51f4cfd99bbf4189> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bffd16ff27899205c51f4cfd99bbf4189 NCIT_P378 "NCI" @default.
- Bffd16ff27899205c51f4cfd99bbf4189 type Axiom @default.
- Bffd16ff27899205c51f4cfd99bbf4189 annotatedProperty IAO_0000115 @default.
- Bffd16ff27899205c51f4cfd99bbf4189 annotatedSource NCIT_C180412 @default.
- Bffd16ff27899205c51f4cfd99bbf4189 annotatedTarget "An orally bioavailable and irreversible covalent inhibitor of Bruton's tyrosine kinase (BTK), with potential antineoplastic activity. Upon oral administration, BTK inhibitor ABBV-992 targets, binds to and inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies. It plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival." @default.